Action OCUL OCULAR THERAPEUTIX, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Ocular Therapeutix, Inc.

Actions

OCUL

US67576A1007

Temps réel estimé Cboe BZX
Autres places de cotation
 18:24:46 02/05/2024 		Varia. 5j. Varia. 1 janv.
5,595 USD +11,45% Graphique intraday de Ocular Therapeutix, Inc. +33,33% +25,56%
18/04 Ocular Therapeutix, Inc. annonce des résultats positifs de phase 1 pour AXPAXLI ? dans la rétinopathie diabétique CI
15/04 Ocular Therapeutix, Inc. annonce des changements au sein de sa direction CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy
Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Ocular Therapeutix CEO Antony Mattessich Steps Down; Pravin Dugel Named Successor
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
Ocular Therapeutix, Inc. Announces Executive Changes
Ocular Therapeutix, Inc. Announces CEO Changes
Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4) to Senior Vice President of Global Head of Biometrics
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Ocular Therapeutix to Present Data at the 2024 ASCRS Annual Meeting
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action OCUL
  4. Actualités Ocular Therapeutix, Inc.
  5. Autres langues